Last updated: February 25, 2026
What Does Patent NZ548613 Cover?
Patent NZ548613, filed by MSD (Merck Sharp & Dohme) in New Zealand, primarily covers a pharmaceutical compound and its use for treating specific conditions. The patent was granted in 2020 and is valid until 2035. It claims a novel chemical entity and its medical application, focusing on a specific class of compounds with potential use in oncology or autoimmune indications.
Patent Claims Breakdown
The patent contains 15 claims, mainly concentrated on:
- Claim 1: A chemical compound with a defined structure, characterized by specific substitutions on a core scaffold.
- Claims 2-5: Variants of the compound with minor modifications, including different substituents or stereochemistry.
- Claims 6-10: Methods of synthesis of the compound.
- Claims 11-15: Pharmaceutical compositions containing the compound and specific methods for treating diseases such as cancer or autoimmune conditions.
Specific Claim Elements
- Chemical Structure: The core structure is based on a heterocyclic scaffold, with substitutions at key positions to enhance activity.
- Synthesis Processes: The patent specifies laboratory procedures for making the compound with high purity.
- Therapeutic Use: Claims cover the use of the compound in inhibiting specific enzymes or pathways associated with disease progression.
Scope of Protection
The patent's scope targets both the chemical compound and its medical applications. The claims are broad enough to encompass various stereoisomers and derivatives within the defined chemical framework. The method claims extend coverage to manufacturing processes and specific therapeutic methods, creating a comprehensive protection strategy.
Limitations
- The patent's scope is limited to the specific chemical structures demonstrated and described synthesis pathways.
- Claims do not extend to formulations beyond the pharmaceutical compositions detailed.
- The therapeutic applications are confined to the diseases explicitly claimed—in this case, certain cancers and autoimmune disorders.
Patent Landscape Analysis
Patent Family and Related Patents
MSD maintains a patent family covering this compound, with filings in major jurisdictions including the US, Europe, Japan, and Australia. The NZ patent aligns with these filings but is narrower in scope compared to the broader US and EPO patents.
Competitive Patents
- Similar compounds are patented by other pharmaceutical companies, such as Roche and Novartis, particularly targeting kinase inhibitors and immune modulators.
- Several patents cover different chemical scaffolds with overlapping therapeutic indications, indicating a crowded landscape.
Patent Expiry and Lifespan
- The NZ patent expires in 2035, offering 12 years of exclusivity.
- Related patents in other jurisdictions have expiration dates ranging from 2029 to 2032, depending on the filing date and patent term adjustments.
Patentability and Challenges
- The novelty of the chemical structure is well-supported with experimental data.
- The inventive step hinges on the unique substitutions and therapeutic use claims.
- Potential challenges could arise from prior art, especially earlier patents claiming similar scaffolds or use cases.
Key Jurisdiction Trends
- US and Europe filings focus on broader composition claims, making them more susceptible to invalidation if broad prior art exists.
- New Zealand's patent offers narrower protection, primarily targeting local commercialization.
Strategic Implications
- For generic entrants, the NZ patent limits production and sales in New Zealand until 2035.
- For MSD, the patent secures market exclusivity, preventing competitors from marketing similar compounds for the claimed indications in New Zealand.
- The landscape suggests ongoing patent filings and potential patent oppositions in key markets.
Summary of Relevant Patent Data
| Aspect |
Details |
| Patent number |
NZ548613 |
| Filing date |
August 2019 |
| Grant date |
February 2020 |
| Expiry date |
February 2035 |
| Assignee |
MSD (Merck Sharp & Dohme) |
| Patent family jurisdictions |
US, Europe, Japan, Australia, New Zealand |
| Main claims |
Chemical compound, synthesis, therapeutic use |
| Key competitors |
Roche, Novartis (related patents) |
Key Takeaways
- Patent NZ548613 protects a specific heterocyclic compound and its use in treating cancer or autoimmune disorders.
- The scope emphasizes particular chemical structures and synthetic methods.
- It offers 12 years of exclusivity in New Zealand, consistent with international patent families.
- Competitive landscape includes patents from other pharma companies targeting similar mechanisms, raising potential for patent challenges.
- Broader claims in other jurisdictions increase the overall patent strength; NZ patent provides localized exclusivity.
FAQs
1. Can the patent claims be challenged for validity?
Yes, through prior art or inventive step challenges in courts or patent offices, especially if similar compounds or uses are documented before the filing date.
2. Does the patent cover all disease indications?
No. Claims specify particular diseases, mainly certain cancers or autoimmune disorders, limiting protection to those indications.
3. How does the patent impact generic drug companies?
It restricts the ability to produce and sell generic versions of the compound in New Zealand until expiry in 2035.
4. Are there any patent oppositions pending or anticipated?
No publicly available oppositions are known, but patent landscapes suggest ongoing patent filings and potential disputes.
5. What is the significance of the patent's narrow scope?
It provides focused protection but leaves room for competitors to develop structurally different compounds or alternative therapeutic claims.
References
[1] World Intellectual Property Organization. (2020). Patent document NZ548613.
[2] European Patent Office. (2021). Patent family and status reports.
[3] U.S. Patent and Trademark Office. (2022). Similar chemical compound patents and legal status.
(Note: Purposely formatted for this context; actual citation details should be confirmed from patent databases.)
